Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Invested Capital (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Invested Capital for 7 consecutive years, with $181.2 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 45.79% to $181.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $181.2 million through Dec 2025, down 45.79% year-over-year, with the annual reading at $181.2 million for FY2025, 45.79% down from the prior year.
  • Invested Capital for Q4 2025 was $181.2 million at Pliant Therapeutics, down from $230.7 million in the prior quarter.
  • The five-year high for Invested Capital was $571.9 million in Q1 2023, with the low at $157.7 million in Q2 2022.
  • Average Invested Capital over 5 years is $329.6 million, with a median of $305.4 million recorded in 2022.
  • The sharpest move saw Invested Capital surged 507.98% in 2021, then plummeted 45.79% in 2025.
  • Over 5 years, Invested Capital stood at $199.1 million in 2021, then skyrocketed by 62.4% to $323.3 million in 2022, then surged by 49.61% to $483.6 million in 2023, then tumbled by 30.88% to $334.3 million in 2024, then tumbled by 45.79% to $181.2 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $181.2 million, $230.7 million, and $250.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.